Vaccination in twin pregnancies: comparison between immunization before conception and during pregnancy.
Humans
Female
Pregnancy
Pregnancy, Twin
/ immunology
Adult
COVID-19
/ prevention & control
COVID-19 Vaccines
/ immunology
Vaccination
Prospective Studies
SARS-CoV-2
/ immunology
Immunoglobulin G
/ blood
Pregnancy Complications, Infectious
/ prevention & control
Antibodies, Viral
/ blood
Antibodies, Neutralizing
/ blood
Spike Glycoprotein, Coronavirus
/ immunology
BNT162b2 Pfizer/BioNTech vaccination
COV-2-Trimeric S-IgG -b1
Neutralizing antibodies
PCR
SARS-CoV-2
Twin pregnancy
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 May 2024
11 May 2024
Historique:
received:
29
05
2023
accepted:
07
05
2024
medline:
12
5
2024
pubmed:
12
5
2024
entrez:
11
5
2024
Statut:
epublish
Résumé
To evaluate the development of neutralizing Anti-Spike Protein IgG (Anti-S-IgG) during twin pregnancies before conception vs. during pregnancy. In this prospective study, three blood samples were collected from pregnant women and subjected to anti-S-IgG immunodiagnostics. The patient's medical records, including vaccination and PCR test results, were collected from the hospital's electronic database. Age-matched non-pregnant women were used as a control group. We enrolled 83 women with twin pregnancies. 49 women were vaccinated before conception, 21 women were vaccinated during pregnancy, and 13 were not vaccinated. Of the 13 women who weren't vaccinated, three became positive during pregnancy, and all three were severely ill. By contrast, in women who were vaccinated during or before pregnancy, COVID-19 infection during pregnancy caused only mild symptoms. A ten-fold lower level of neutralizing Anti-S-IgG in the 3rd trimester was observed in healthy women who were vaccinated before conception and remained healthy until discharge from the hospital after delivery 1605 (IQR: 763-2410) compared to the healthy women who were vaccinated during pregnancy 152 AU/mL (IQR: 54-360). This difference was higher among women who were infected by COVID-19 (as verified by a positive PCR test). The third-trimester level of neutralizing Ant-S-IgG in the infected group was 4770 AU/mL (4760-6100) in infected women vaccinated before conception compared to those vaccinated during pregnancy who had 70 AU/mL (IQR: 20-170) (p < 0.001). In women vaccinated at 13-16 weeks gestation, neutralizing Anti-S-IgG at 20-22 weeks went up to 372 AU/mL (IQR: 120-1598) but rapidly dropped to 112 AU/mL (IQR: 54-357) at 28-30 weeks, (p < 0.001), a faster decline than in women vaccinated at a median 22 weeks before conception. Being infected by COVID-19 before conception was linked to having low Anti-S-IgG levels during pregnancy, whereas being infected by COVID-19 during pregnancy led to a very high response in the 3rd trimester. In twin pregnancies, significantly lower neutralizing Anti-S-IgG levels were observed in women vaccinated during pregnancy compared to those vaccinated before conception, whether infected or not infected by COVID-19. A full course of vaccination before conception is recommended.Trial registration. ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: October 4, 2021. https://clinicaltrials.gov/ ID: NCT04595214.
Identifiants
pubmed: 38734805
doi: 10.1038/s41598-024-61504-6
pii: 10.1038/s41598-024-61504-6
doi:
Substances chimiques
COVID-19 Vaccines
0
Immunoglobulin G
0
Antibodies, Viral
0
Antibodies, Neutralizing
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Banques de données
ClinicalTrials.gov
['NCT04595214']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
10813Subventions
Organisme : Erapermed project
ID : # JTC2019-61
Organisme : Erapermed project
ID : # JTC2019-61
Organisme : Erapermed project
ID : # JTC2019-61
Organisme : Erapermed project
ID : # JTC2019-61
Organisme : Erapermed project
ID : # JTC2019-61
Organisme : Erapermed project
ID : # JTC2019-61
Organisme : Erapermed project
ID : # JTC2019-61
Organisme : Erapermed project
ID : # JTC2019-61
Organisme : Erapermed project
ID : # JTC2019-61
Organisme : Erapermed project
ID : # JTC2019-61
Organisme : Israel Ministry of Health Project
ID : # 2020166
Organisme : Israel Ministry of Health Project
ID : # 2020166
Organisme : Israel Ministry of Health Project
ID : # 2020166
Organisme : Israel Ministry of Health Project
ID : # 2020166
Organisme : Israel Ministry of Health Project
ID : # 2020166
Organisme : Israel Ministry of Health Project
ID : # 2020166
Organisme : Israel Ministry of Health Project
ID : # 2020166
Organisme : Israel Ministry of Health Project
ID : # 2020166
Organisme : Israel Ministry of Health Project
ID : # 2020166
Organisme : Israel Ministry of Health Project
ID : # 2020166
Organisme : Shamir Medical Center "Taftafot"
ID : grant #12/2021
Informations de copyright
© 2024. The Author(s).
Références
Msemburi, W. et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature 613(7942), 130–137 (2023).
doi: 10.1038/s41586-022-05522-2
pubmed: 36517599
Juan, J. et al. Effect of coronavirus disease 2019 (COVID-19) on the maternal, perinatal and neonatal outcome: Systematic review. Ultrasound Obstet. Gynecol. 56, 15–27 (2020).
doi: 10.1002/uog.22088
pubmed: 32430957
pmcid: 7276742
Crovetto, F. et al. Seroprevalence and presentation of SARS-CoV-2 in pregnancy. Lancet 396, 530–531 (2020).
doi: 10.1016/S0140-6736(20)31714-1
pubmed: 32771084
pmcid: 7831869
Mor, M. et al. Impact of the COVID-19 pandemic on excess perinatal mortality and morbidity in Israel. Am. J. Perinatol. 38, 398–403 (2021).
doi: 10.1055/s-0040-1721515
pubmed: 33302306
DeBolt, C. A. et al. Pregnant women with severe or critical coronavirus disease 2019 have increased composite morbidity compared with nonpregnant matched controls. Am. J. Obstet. Gynecol. 224, 510.e1-510.e12 (2021).
doi: 10.1016/j.ajog.2020.11.022
pubmed: 33221292
Liu, H. et al. Why are pregnant women susceptible to COVID-19? An immunological viewpoint. J. Reprod. Immunol. 139, 103122 (2020).
doi: 10.1016/j.jri.2020.103122
pubmed: 32244166
pmcid: 7156163
Sheikh, J. et al. Global variations in the burden of SARS-CoV-2 infection and its outcomes in pregnant women by geographical region and country’s income status: A meta-analysis. BMJ Glob Health 7, e010060 (2022).
doi: 10.1136/bmjgh-2022-010060
pubmed: 36368768
Toussia-Cohen, S. et al. Maternal and neonatal immune responses following COVID-19 infection and vaccinations in pregnancy. Vaccines 10, 2019 (2022).
doi: 10.3390/vaccines10122019
pubmed: 36560429
pmcid: 9782019
Marín-Cos, A. et al. Maternal vaccination greatly depends on your trust in the healthcare system: A qualitative study on the acceptability of maternal vaccines among pregnant women and healthcare workers in Barcelona, Spain. Vaccines 10, 2015 (2022).
doi: 10.3390/vaccines10122015
pubmed: 36560425
pmcid: 9783547
Hadlock, F. P., Shah, Y. P., Kanon, D. J. & Lindsey, J. V. Fetal crown-rump length: Reevaluation of relation to menstrual age (5–18 weeks) with high-resolution real-time US. Radiology 182, 501–505 (1992).
doi: 10.1148/radiology.182.2.1732970
pubmed: 1732970
Jung, K. et al. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls. J. Clin. Lab. Anal. 35, e23921 (2021).
doi: 10.1002/jcla.23921
pubmed: 34369009
pmcid: 8418513
Jiang, Y. et al. Establishment of quantitative RT-PCR detection of SARS-CoV-2 virus. Eur. J. Med. Res. 26, 147 (2021).
doi: 10.1186/s40001-021-00608-5
pubmed: 34920757
pmcid: 8677905
Mulchandani, R. et al. Accuracy of UK Rapid Test Consortium (UK-RTC) “AbC-19 Rapid Test” for detection of previous SARS-CoV-2 infection in key workers: Test accuracy study. BMJ 371, 4262 (2020).
doi: 10.1136/bmj.m4262
Infantino, M. et al. The WHO International Standard for COVID-19 serological tests: Towards harmonization of anti-spike assays. Int. Immunopharmacol. 100, 108095. https://doi.org/10.1016/j.intimp.2021.108095 (2021).
doi: 10.1016/j.intimp.2021.108095
pubmed: 34619529
pmcid: 8403673
Sunder, A. et al. Maternal COVID-19 disease and COVID-19 immunization. Cureus. 14, e28328 (2022).
pubmed: 36168383
pmcid: 9500403
Sunder, A. et al. COVID-19 vaccinations in pregnancy: Save mother and baby from COVID-19 pandemic. Int. J. Gynaecol. Obstet. https://doi.org/10.1002/ijgo.14532 (2022).
doi: 10.1002/ijgo.14532
pubmed: 36306398
pmcid: 9874773
Maymon, R., Meiri, H., Svirski, R., Weiner, E. & Cuckle, H. Maternal serum screening marker levels in twin pregnancies affected by gestational diabetes. Arch. Gynecol. Obstet. 299, 655–663 (2019).
doi: 10.1007/s00404-018-5010-3
pubmed: 30569341
Maymon, R. et al. Developing a new algorithm for first and second-trimester preeclampsia screening in twin pregnancies. Hypertens. Preg. 36, 108–115 (2017).
doi: 10.1080/10641955.2016.1242605
Nevo, L. et al. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose. Am J Obstet Gynecol. 227, 486.e1-486.e10 (2022).
doi: 10.1016/j.ajog.2022.04.010
pubmed: 35430228
COVID-19 Projections—Institute for Health Metrics and Evaluation, https://www.who.int/news/item/20-05-2022-world-health-statistics-2022
Etti, M. et al. Maternal vaccination: A review of current evidence and recommendations. Am. J. Obstet. Gynecol. 226, 459–474 (2022).
doi: 10.1016/j.ajog.2021.10.041
pubmed: 34774821
Deng, J. et al. Association of infection with different SARS-CoV-2 variants during pregnancy with maternal and perinatal outcomes: A systematic review and meta-analysis. Int. J. Environ. Res. Public Health. 19, 15932 (2022).
doi: 10.3390/ijerph192315932
pubmed: 36498007
pmcid: 9740636
Vazquez-Pagan, A. & Schultz-Cherry, S. Serological responses to influenza vaccination during pregnancy. Microorganisms. 9, 2305 (2021).
doi: 10.3390/microorganisms9112305
pubmed: 34835431
pmcid: 8619416
Abraham, C., Pichichero, M., Eisenberg, J. & Singh, S. Third-trimester maternal vaccination against pertussis and pertussis antibody concentrations. Obstet. Gynecol. 131, 364–369 (2018).
doi: 10.1097/AOG.0000000000002438
pubmed: 29324612
Malinowski, A. K., Noureldin, A. & Othman, M. COVID-19 susceptibility in pregnancy: Immune/inflammatory considerations, the role of placental ACE-2 and research considerations. Reprod Biol. 20, 568–572 (2020).
doi: 10.1016/j.repbio.2020.10.005
pubmed: 33183974
pmcid: 7832785
Shen, C. J. et al. Evaluation of transplacental antibody transfer in SARS-CoV-2-immunized pregnant women. Vaccines 10, 101 (2022).
doi: 10.3390/vaccines10010101
pubmed: 35062762
pmcid: 8778956
Larcade, R. et al. Maternal-fetal immunologic response to SARS-CoV-2 infection in a symptomatic vulnerable population: A prospective cohort. J Infect Dis. 225, 800–809 (2022).
doi: 10.1093/infdis/jiab591
pubmed: 34865064
Moriarty, K. et al. COVID-19 and differential effects in twins: Insights from placenta pathology. Placenta 124, 162–166. https://doi.org/10.1016/j.placenta.2022.05.014 (2022).
doi: 10.1016/j.placenta.2022.05.014